Joel Isaacson & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

Joel Isaacson & Co’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-9,000	Closed	-$57K	–	213
2016 Q4	$57K	Hold	9,000	–	–	0.01%	288
2016 Q3	$40K	Hold	9,000	–	–	0.01%	361
2016 Q2	$26K	Hold	9,000	–	–	0.01%	419
2016 Q1	$25K	Hold	9,000	–	–	0.01%	447
2015 Q4	$93K	Hold	9,000	–	–	0.02%	244
2015 Q3	$103K	Sell	9,000 -3,000	-25%	-$40K	0.03%	224
2015 Q2	$179K	Hold	12,000	–	–	0.05%	179
2015 Q1	$108K	Hold	12,000	–	–	0.03%	247
2014 Q4	$146K	Hold	12,000	–	–	0.04%	191
2014 Q3	$117K	Hold	12,000	–	–	0.04%	184
2014 Q2	$153K	Hold	12,000	–	–	0.05%	157
2014 Q1	$127K	Hold	12,000	–	–	0.04%	176
2013 Q4	$91K	Hold	12,000	–	–	0.03%	198
2013 Q3	$87K	Hold	12,000	–	–	0.04%	193
2013 Q2	$19K	Buy	+12,000	New	+$20.7K	0.01%	329

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Joel Isaacson & Co's BCRX Position: Q1 2017 in Review

Joel Isaacson & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2017, closing a stake of 9,000 shares — an estimated $57K sold.

Joel Isaacson & Co first reported a position in BCRX in Q2 2013 and held it in 15 quarters. The position peaked at $179K in Q2 2015. 117 funds tracked by Wall St. Rank hold BCRX as of Q1 2017.

Joel Isaacson & Co reported no remaining BioCryst Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Joel Isaacson & Co sold 9,000 BioCryst Pharmaceuticals shares in Q1 2017, an estimated $57K.
Joel Isaacson & Co first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Joel Isaacson & Co's BioCryst Pharmaceuticals position peaked at $179K in Q2 2015.
117 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2017.

Based on Joel Isaacson & Co's 13F filing for Q1 2017, filed 5 May 2017.